Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-01-13
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Negotiated without a prior call for competition
CPV classification: 33000000 | 33696500 | 38000000
Estimated value: 24000000 NOK

Technical requirements: Oslo University Hospital Trust intends to enter into a framework agreement with Genome Products BV for the delivery of NGSgo kits with the accompanying software for HLA typing.
The contract will be entered into as a procurement without a contest in accordance with the Public Procurement Regulations, section 13-4 letter b).
Oslo University Hospital Trust aims to sign a contract shortly after the deadline stated in the Public Procurement Regulations, section 25-3 of ten days after publication of this announcement has expired.
HLA typing is used when assessing transplants for critically ill patients who require bone marrow, and for other transplant matching. The analysis results must be transferred electronically from the analysis software to the laboratory computer system Orpheus. Such connection and installation is necessary in order to minimise the risk of wrong diagnostics.
After an open tender contest in 2015/2016, a contract was signed with Genome Products BV and its analysis software was connected to Orpheus. The connection to Orpheus was specially adapted for the current analysis software. Any change would lead to an unacceptable risk that the adaptations required in Orpheus cannot be done either technically, or within a reasonable implementation period. Therefore a necessary requirement for NGS HLA typing kits is that they can be analysed with the analysis software from Genome Products BV.
The option for an annual extension for as long as the department uses the Orpheus laboratory system, and the challenges involved in changing the analysis programme are the same.
Comments concerning the value stated in point II.1.7: The procurement and the annual value of the contract are approx. NOK 4 million. The contract duration is one year, with an option for an annual extension for maximum five times. I.e., a maximum length of six years.
Genome Products BV currently have a monopoly on the sale/delivery of NGSgo and GenDx products with the accompanying analysis software. HLA typing is used when assessing transplants for critically ill patients who require bone marrow, and for other transplant matching. The analysis results must be transferred electronically from the analysis software to the laboratory computer system Orpheus. The connection to Orpheus was specially adapted for the current analysis software. Any change would lead to an unacceptable risk that the adaptations required in Orpheus cannot be done either technically, or within a reasonable implementation period. It is unrealistic that the necessary connections and installations of the required analysis programme will be ready for use within a reasonable period from the award of any new contract. Such connections and installation are, at the same time, an essential requirement for the department being able to use any new HLA typing kits. Therefore a necessary requirement for NGS HLA typing kits is that they can be analysed with the analysis software from Genome Products BV.


Winner: Genome Products BV
Award value: 24000000